Women with a higher risk of developing breast cancer are set to be offered a pill that cuts their risk of developing the disease in half. NHS England and UK medication watchdogs announced the pill ...

Please provide your email address to receive an email when new articles are posted on . Adding the ER antagonist fulvestrant to anastrozole provided no benefit to women with hormone-receptor-positive ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Postmenopausal women with ductal carcinoma in situ experienced comparable rates of recurrence but ...

Evaluation of Mena isoforms as a surrogate for epithelial mesenchymal transformation and erlotinib resistance in breast carcinoma No significant financial relationships to disclose. This is an ASCO ...

August 7, 2006 — Anastrazole should now be the preferred initial adjuvant treatment for postmenopausal women with hormone-sensitive early-stage breast cancer, instead of the current standard, ...

Enclomiphene is a non-steroidal selective estrogen receptor modulator (SERM) sometimes used to treat male secondary hypogonadism, or low testosterone caused by problems with the hypothalamus or ...

Study author Jack Cuzick, MD, Queen Mary University, London, United Kingdom, explained that another endocrine therapy, tamoxifen, has previously been demonstrated to have a similar extended effect in ...

Faslodex (fulvestrant) improved overall survival by nearly six months compared with anastrozole as initial hormone therapy for postmenopausal women with estrogen receptor-positive advanced breast ...

Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Carpal tunnel ...

Waldenström's macroglobulinemia is a lymphoproliferative disorder characterized by a lymphoplasmacytic bone marrow infiltrate and high levels of a monoclonal IgM in serum. 1 A number of ...

The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of estrogen receptors. We hypothesized that these two agents in combination might be more ...